ARCHIMED Acquires BioVendor Group

ARCHIMED Diagnostics Acquires 60% Stake in ARK Diagnostics

October 28, 2025

Medical Devices

ARCHIMED Diagnostics (ARCHIMED’s diagnostics team) has acquired a 60% stake in Fremont-based ARK Diagnostics from Soulbrain Holdings in a transaction valuing ARK at $428 million. Soulbrain retains and reinvests in a 40% stake and the deal includes a joint-venture agreement to accelerate ARK’s product development and global expansion.

ARCHIMED (via MED Platform I) Acquires Majority Stake in SUANFARMA

November 18, 2021

Pharmaceuticals

Transatlantic healthcare-focused private equity firm ARCHIMED, through its MED Platform I (MPI) fund, has acquired a majority stake in Madrid-based SUANFARMA, a manufacturer and distributor of active pharmaceutical ingredients (APIs) and nutraceutical ingredients. Ares Management provided debt financing for the transaction; SUANFARMA founder Héctor Ara and members of management rolled a material minority stake into the business and remain significant shareholders.

ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)

November 3, 2021

Biotechnology

Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.

ARCHIMED Acquires Majority Stake in Xpress Biologics

October 5, 2021

Biotechnology

ARCHIMED has acquired a majority stake in Liège-based Xpress Biologics and will finance a ten-fold expansion of the company's plasmid DNA production capacity with the implementation of GMP services. Founders Christian Rodriguez, Philippe Ledent and Marc Daukandt, together with public investor Noshaq, will reinvest proceeds; ARCHIMED is investing via its MED II fund to help internationalize distribution into the US and Asia‑Pacific.

ARCHIMED Acquires Majority Stake in Germany's Zyto Group

January 12, 2021

Medical Devices

ARCHIMED, through its MED II fund, has acquired a majority stake in the Zyto group — a German developer, manufacturer and distributor of advanced cancer diagnostics, including Zytomed, ZytoVision and 42 Life Sciences. The deal will keep founders and management as significant minority shareholders and is intended to accelerate product innovation, regulatory capabilities and international expansion of the group's precision oncology diagnostics.

ARCHIMED Acquires Direct Healthcare Group from NorthEdge

December 12, 2019

Medical Devices

ARCHIMED, a European healthcare-focused private equity firm, has acquired Direct Healthcare Group (DHG) from NorthEdge Capital. ARCHIMED plans to support DHG's international expansion and continued buy-and-build strategy across Europe, providing significant committed capital for future acquisitions.